**Supplementary Table 5. Safety analysis of patients with decompensated cirrhosis.**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Event** | **Studies** | **N** | **Pool** | **95% CI** | | ***p-*value** | **I2** |
| **L** | **H** |
| DC AE | 8 | 1141 | 69.0% | 48.6% | 86.2% | <0.01 | 98% |
| DC SAE | 15 | 2547 | 16.2% | 10.8% | 22.4% | <0.01 | 93% |
| DC HCC | 7 | 1433 | 3.1% | 1.50% | 5.0% | 0.01 | 63% |
| DC mortality | 16 | 2832 | 4.6% | 3.10% | 6.3% | <0.01 | 69% |
| AE SOF/VEL±RBV | 5 | 544 | 64.2% | 34.0% | 89.4% | 0.84 | 98% |
| AE SOF/LDV±RBV | 2 | 407 | 77.5% | 27.9% | 100% | 99% |
| AE SOF/DCV±RBV | 2 | 190 | 62.1% | 39.1% | 82.6% | 81% |
| SAE SOF/VEL±RBV | 5 | 544 | 16.2% | 7.5% | 27.3% | 0.94 | 88% |
| SAE SOF/LDV±RBV | 3 | 755 | 20.3% | 3.6% | 45.7% | 98% |
| SAE SOF/DCV±RBV | 6 | 797 | 15.9% | 8.0% | 25.7% | 91% |
| HCC SOF/VEL±RBV | 1 | 102 | 2.9% | 0.4% | 7.3% | 0.95 | -% |
| HCC SOF/LDV±RBV | 3 | 457 | 3.6% | 0.7% | 8.2% | 73% |
| HCC SOF/DCV±RBV | 2 | 426 | 2.9% | 0.1% | 8.7% | 85% |
| mortality SOF/VEL±RBV | 7 | 877 | 3.8% | 1.7% | 6.5% | 0.95 | 62% |
| mortality SOF/LDV±RBV | 4 | 1099 | 3.8% | 1.7% | 6.6% | 77% |
| mortality SOF/DCV±RBV | 5 | 773 | 6.7% | 3.9% | 10.1% | 65% |
| SOF-based AE | 6 | 418 | 52.9% | 28.0% | 77.1% | 0.03 | 96% |
| SOF-based+RBV AE | 6 | 723 | 89.2% | 68.1% | 99.9% | 97% |
| SOF-based SAE | 7 | 681 | 12.8% | 7.50% | 19.1% | 0.03 | 74% |
| SOF-based+RBV SAE | 6 | 721 | 24.9% | 16.3% | 34.7% | 82% |
| SOF-based HCC | 3 | 344 | 1.60% | 0.00% | 4.4% | 0.62 | 28% |
| SOF-based+RBV HCC | 2 | 539 | 3.50% | 0.2% | 9.9% | 87% |
| SOF-based mortality | 7 | 750 | 3.10% | 0.80% | 6.40% | 0.24 | 72% |
| SOF-based+RBV mortality | 6 | 1052 | 5.80% | 3.0% | 9.4% | 73% |
| 12W SOF-based±RBV AE | 7 | 941 | 68.7% | 46.4% | 87.2% | 0.17 | 98% |
| 24W SOF-based±RBV AE | 3 | 200 | 85.1% | 71.9% | 94.8% | 79% |
| 12W SOF-based±RBV SAE | 8 | 1347 | 20.2% | 12.9% | 28.5% | 0.77 | 91% |
| 24W SOF-based±RBV SAE | 4 | 347 | 21.8% | 13.2% | 31.8% | 75% |
| 12W SOF-based±RBV HCC | 4 | 995 | 4.10% | 2.60% | 6.00% | 0.34 | 34% |
| 24W SOF-based±RBV HCC | 2 | 132 | 2.10% | 0.10% | 5.50% | 0% |
| 12W SOF-based±RBV mortality | 9 | 1068 | 3.6% | 1.90% | 5.70% | 0.36 | 51% |
| 24W SOF-based±RBV mortality | 5 | 631 | 5.6% | 2.60% | 9.5% | 69% |
| SOF/VEL AE | 4 | 374 | 50.2% | 18.9% | 81.4% | 0.008 | 97% |
| SOF/VEL+RBV AE | 3 | 170 | 91.1% | 85.4% | 95.6% | 20% |
| CC SOF-based±RBV AE | 2 | 272 | 70.8% | 30.7% | 97.8% | 0.93 | 97% |
| DC SOF-based±RBV AE | 8 | 1141 | 69.0% | 48.6% | 86.2% | 98% |
| CC SOF-based±RBV SAE | 5 | 3418 | 2.80% | 0.9% | 5.7% | <0.001 | 88% |
| DC SOF-based±RBV SAE | 15 | 2547 | 16.2% | 10.8% | 22.4% | 93% |
| CC SOF-based±RBV HCC | 4 | 2752 | 0.00% | 0.00% | 0.9% | 0.001 | 55% |
| DC SOF-based±RBV HCC | 7 | 1433 | 3.10% | 1.50% | 5.0% | 63% |
| CC SOF-based±RBV mortality | 3 | 363 | 0.5% | 0.2% | 0.8% | <0.001 | 0% |
| DC SOF-based±RBV mortality | 16 | 2832 | 4.6% | 3.10% | 6.30% | 69% |

SOF, sofosbuvir; LDV, ledipasvir; VEL, velpatasvir; DCV, daclatasvir; SIM, simeprevir; RBV, ribavirin; SVR, sustained virologic response; Child-Pugh grade of cirrhosis, A, B, C; DC, decompensated cirrhosis; CC, compensatory cirrhosis. AE, adverse event; SAE, serious adverse event; HCC, hepatocellular carcinoma; Mortality, death.